Investigator sites provide an essential connection between drug development sponsors and patients in clinical trials—and play a key role in producing high-quality data. To better support a site’s day-to-day study activities and make a difference for patient care, Labcorp Central Laboratory Services (CLS) is continually evaluating current practices and implementing …
Expanded crop protection and chemical testing: For those committed to our planet’s sustainability and the welfare of humanity
We’ve been ramping up our product testing support at some of our European sites over the past few years to meet the needs of the rapidly growing crop protection and chemical industry. Now, we’re excited to announce a multimillion-dollar expansion at our Greenfield, Indiana campus in the U.S. that enhances …
Antibody Critical Reagents: Challenges and Risks in Their Lifecycle Management
Antibody critical reagents are crucial to regulated (GxP) drug development assays. Poor quality reagents risk generating inaccurate and unreliable results, while failure in supply can delay preclinical and clinical studies. Overall, the potential consequences are losses in time, money and reputation. Read on to understand the key challenges in antibody …
A Creative Solution to Address the Biosimilar Boom
Identifying viable study sites presents a challenge in many clinical trials. Biosimilar development is especially challenging as the number of sponsors preparing to broaden access to today’s blockbuster biologics, by providing lower-cost biosimilar alternative, continues to grow. While this flood of research activity will make a significant improvement for patient …
Labcorp Expanding Bioanalytical Service Offering in Asia Pacific with Integrated Laboratory in Singapore
To meet the increased demand of pharmaceutical and biotechnology companies and drive continued growth, we are pleased to announce the expansion of its bioanalytical operations in Asia-Pacific. This new laboratory in Singapore will be co-located with its Central Laboratory Services.
Webinar: Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery
On April 15, we hosted the virtual conference, “Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery.” For study teams working to develop treatments for patients suffering from neurodegenerative diseases, the need to leverage new techniques quickly and effectively is imperative. This topic is vital, as nearly 50 million people worldwide suffer …
Decentralized Clinical Trials (DCT) Monthly Blog – March 2021
This month, we want to highlight the growing connections between decentralized clinical trials (DCTs) and the critical therapeutic area of oncology.
Expanding clinical trial support in Europe, the Middle East and Africa with a new automated kit production line
As part of a global growth and expansion strategy, we’re announcing the spring opening of a new kit production line at our European Operations Center (EOC). Based in Mechelen, Belgium, the EOC is a multi-use facility that handles dry ice production and distribution for the EU, as well as study …
Minimal Residual Disease by Flow Cytometry: Latest Insights on Validation
Despite the development of cellular and antibody-based therapeutics that eliminate malignant cells, patients who have achieved complete remission or response may experience relapse. Increasing evidence suggests that the presence of measurable/minimal residual disease (MRD) in bone marrow (BM) tissue is one, if not the strongest, prognostic factor for disease outcome …
Innovation in Plasma Cell Enrichment for Multiple Myeloma Studies
Syndecan-1 (SDC1), also known as CD138, is a well-known and specific plasma cell marker that is highly expressed on the surface of multiple myeloma plasma cells. As it can be a challenge detecting the small number of malignant plasma cells within the large proportion of cells obtained from a bone …